INTRODUCTION
Malaria is a debilitating disease transmitted by mosquitoes and caused by protozoa of the genus Plasmodium. Plasmodium falciparum causes the most serious illness and the asexual blood stage that replicates in erythrocytes may lead to coma and death within a few days. Due to emerging resistance against current anti-malarial drugs, there is an urgent need to identify new chemotherapeutic targets in malaria.
One candidate target is myristoyl-CoA : protein N-myristoyltransferase (NMT ; EC 2.1.3.97). NMT catalyses the cotranslational transfer of the C "% : ! fatty acid from myristoyl-CoA to the N-terminal glycine of a variety of cellular proteins [1] . There are several reasons why NMT may be an attractive target for chemotherapy of infectious eukaryotes, and it has been investigated in the context of fungal infections [2] . The activity of this acyltransferase is essential for fungal viability [3, 4] and in Saccharomyces cere isiae NMT is an essential gene [5] . Although the binding site for the acyl-CoA is highly conserved, the protein binding site is variable [6, 7] , and peptide binding studies suggest that the protein substrate specificity has diverged in different species [8] . Significant differences between NMT in humans and fungi have led to the design of peptidomimetic inhibitors, which are highly selective against Candida albicans NMT compared with the human enzyme [9, 10] . These studies suggest that NMT is a potential target for chemotherapeutic drugs against fungal infections and should be investigated in the context of parasitic infections.
Recently the structure of the C. albicans apoenzyme [11] and a ternary complex of the S. cere isiae enzyme with bound myristoyl-CoA and peptide substrate analogues [12] have been reported, allowing the identification of the residues involved in protein with that derived from the human gene showed a different pattern of inhibition by chemical modification. Human NMT activity was inhibited by diethylpyrocarbonate and partially inhibited by iodacetamide, whereas P. falciparum NMT activity was not inhibited by either pre-treatment. Since the enzyme in infectious fungi is a target for potential chemotherapeutic drugs, it should also be investigated in the context of parasitic infections such as that responsible for malaria.
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substrate binding and a proposed catalytic mechanism. It has been proposed that acyl transfer occurs through a direct nucleophilic attack of the glycine nitrogen on the carbonyl carbon of the thioester of myristoyl-CoA, following polarization of the carbonyl in an oxyanion hole and proton transfer from the glycine α-amino group to the C-terminal carboxylate of NMT [12] . The NMT enzyme activity is not dependent on its N-terminal sequence. The first 59 amino acids of the yeast enzyme appear to be unnecessary for enzymic activity [7] . In mammalian cells a number of different-sized forms have now been described, resulting from transcription from two loci [13] , differential mRNA splicing [14] and proteolytic cleavage of the N-terminus [15] . The extended form of NMT appears to contain a ribosomal targeting sequence [16] .
Although there have been few studies that directly demonstrate N-myristoylation of P. falciparum proteins, potential substrates such as the ADP-ribosylation factor 1 (ARF1) have been identified [17] . Metabolic labelling studies in pathogenic fungi have identified the ADP-ribosylation factors as major substrates for NMT [2] , which require N-myristoylation for biological activity. Here we report the cloning and sequence analysis of the P. falciparum NMT, describe expression studies in Escherichia coli and carry out an initial comparison between the parasite and human enzymes.
MATERIALS AND METHODS

Preparation of P. falciparum parasites, and extraction of nucleic acids
P. falciparum clone T9\96 was maintained in erythrocytes in continuous culture, as described previously [18] . Infected ery-throcytes were harvested by centrifugation at 400 g for 5 min, washed twice with ice-cold PBS, and then lysed by the addition of 1 % (v\v) acetic acid to release the intracellular parasites. After addition of a large volume of ice-cold PBS, the parasites were harvested by centrifugation at 400 g for 5 min, washed twice with ice-cold PBS, and then stored at k70 mC.
Nucleic acids were prepared from the parasite material. The frozen extracts were thawed and genomic DNA prepared using the Blood and Cell Culture Genomic DNA Maxi Kit (Qiagen), according to the manufacturer's instructions. Total RNA was prepared from 3.8i10* infected red cells using the SNAP4 Kit (Invitrogen) according to the manufacturer's guidelines. Approx. 200 ng of RNA was used for cDNA synthesis using the cDNA Cycle Kit for reverse transcriptase PCR (RT-PCR ; Invitrogen).
PCR amplification with degenerate primers, isolation of a specific DNA fragment, analysis of products from Vectorette libraries, and assembly of the genomic sequence for P. falciparum NMT In the first step to cloning P. falciparum NMT, degenerate oligonucleotide primers were synthesized, based on regions of amino acid sequence homology between NMT of six different organisms, and biased for P. falciparum codon usage. Two primers, NMT2F [CCA\T GTA\T T\CTA\T ATA\T AAA GAA A\GTA\T AC (forward PVLIKEV\IT)] and NMT3R [CC ATC A\TCC NNN A\TCC AAA TTT (reverse KFGXGDG)], produced an approx. 630 bp product by PCR amplification from genomic DNA. This was confirmed to be part of the NMT gene by sequence analysis.
In the second step a specific probe was used to screen a Southern blot and clone a hybridizing fragment. A 480 bp sequence was amplified by PCR from the partial NMT sequence, and labelled with [α-$#P]dATP (Amersham), using the Prime-It II Random Labelling Kit (Stratagene), according to the manufacturer's guidelines. Southern blotting was carried out using 5 µg of P. falciparum genomic DNA digested with several restriction enzymes. The DNA was transferred to Hybond-Nj Nylon membranes (Amersham) overnight in 20iSSC (where 1iSSC is 0.15 M NaCl\0.015 M sodium citrate) and immobilized by UV cross-linking. After probe addition and washing under high-stringency conditions (final wash in 0.1iSSC\0.1 % SDS at 65 mC for 15 min), hybridizing fragments were identified. Based on the result of the Southern blotting, a fragment hybridizing to the probe was cloned from a library prepared in λ-ZAP II (Stratagene) from size-fractionated BglII-digested genomic DNA. This fragment was sequenced and found to extend 3h from a BglII site within the NMT gene. At this stage a shotgun sequence (PF2MJ) read in The Institute for Genome Research P. falciparum genome database was found to overlap the sequence obtained and it was used to extend the sequence for an additional 150 bp in the 5h direction. These preliminary sequence data were obtained from The Institute for Genomic Research website (http :\\www.tigr.org). This sequencing was part of the International Malaria Genome Sequencing Project.
In the final step to obtain the full sequence of P. falciparum NMT two rounds of Vectorette-II PCR were used to clone the remainder of the gene. Vectorette-II libraries were made according to the manufacturer's guidelines (Genosys) using 0.1 µg of T9\96 genomic DNA digested with either AluI, or DraI. PCR reactions were carried out in 100 µl reaction volumes, using 1 µl of each Vectorette-II library, 250 nM of Universal Vectorette Primer, 250 nM of NMT-specific primer, either NMTVEC2 (AAC ACA TAA AAA ATT CAC CAC AGC) or NMTVEC4 (GAT ATA AAT CCC TAC CAA CAA A), and 5 units of AmpliTaq Gold (Perkin-Elmer). Thermal cycling was as follows :
Cloning full-length P. falciparum NMT from genomic DNA and cDNA and confirmation of the putative translational start site
To confirm the full-length NMT sequence, and to allow insertion of the DNA into an expression vector, it was amplified from both genomic DNA and cDNA using two primers, termed NMTORF1A and NMTORF2A. NMTORF1A (GGATCCCG AAT GAT GAT AAG AAA GAT TTT GTT GG) contained an artificial BamH1 restriction site (underlined) and NMTORF2A (G GAATTC AAG ATG GTG GTT ATA AAC TTA TAA TAA AAC) contained an artificial EcoRI restriction site. PCR reactions used 100 ng of genomic DNA or 50 ng of cDNA and KlenTaq Polymerase (Clontech). Cycling conditions were 94 mC for 5 min for 1 cycle, 94 mC for 1 min, 64 mC for 30 s, 68 mC for 2 min, for 30 cycles, followed by a final extension step of 68 mC for 10 min. PCR products were ligated into the TA vector used to transform E. coli TOP10, and the sequence of chosen inserts was obtained by automatic sequencing using an ABI 377 machine.
The absence of an additional intron 5h of the putative translational initiation site was confirmed by amplification using both genomic and cDNA as DNA templates using the primers NMTUP4 (CGT TAA AAT AAA ATA AAC C) and NMTVEC4. Products were analysed by agarose gel electrophoresis and cloned and sequenced.
Expression of P. falciparum NMT in E. coli
The NMT open reading frame (ORF) was ligated into the expression plasmid pTrcHis-C (a vector that directs expression of the inserted sequence as a polypeptide fused to six histidine residues and the Xpress4 epitope at the N-terminus), the DNA was used to transform E. coli TOP10 cells, and the DNA sequence was confirmed in a chosen clone. Bacteria from a single colony were grown overnight at 37 mC in Terrific Broth, the culture was diluted 20-fold, and after a further 2 h (D '!! , 0.6-1.0) protein expression was induced by addition of 1 mM isopropyl β--thiogalactoside and overnight incubation at 37 mC. Bacterial cells were harvested by centrifugation and resuspended in 1 ml of lysis buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 10 mM imidazole and Complete4 Protease Inhibitor Cocktail EDTA-free from Boehringer Mannheim). They were then lysed by addition of lysozyme to a final concentration of 1 mg:ml −" on ice for 30 min followed by sonication in a Sonics and Materials VibraCell Sonicator, for 4i15 s bursts on maximum deflection. The lysate was cleared by centrifugation (147 000 g, 1 h at 4 mC) and loaded on to a Ni# + -nitrilotriacetate (Ni-NTA) column (Qiagen), equilibrated with lysis buffer. The column was washed twice with wash buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl and 20 mM imidazole), and then the bound protein was eluted from the column using elution buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl and 1.0 M imidazole). The expressed protein was detected by Western blotting, using the Anti-Penta His (Qiagen) or the Anti-Xpress4 Antibodies (Invitrogen). The blot was developed using a secondary antibody conjugated to horseradish peroxidase and ECL2 reagents (Pierce), and exposed to X-Omat film (Kodak) for 10-30 s. Protein concentration was estimated using the BCA (bicin-choninic acid) assay according to the manufacturer's guidelines and the reactions were incubated at 65 mC for 1 h.
NMT activity and inhibition assays
The assay was based on that of King and Sharma [19] that measures the ability of active NMT to transfer [$H]myristate from [$H]myristoyl-CoA, to the N-terminal glycine of a synthetic peptide in itro. The assay was performed using human NMT (kindly provided by Dr Jeffrey McIlhinney [20] ) and P. falciparum NMT expressed in E. coli. A peptide, termed PfG8, was designed based on the N-terminal sequence of the P. falciparum ARF1 protein. This peptide contained the sequence Gly-Leu-Tyr-ValSer-Arg-Leu-Phe and conformed to the consensus sequence required for the N-myristoylation of proteins by NMT. The peptide sequence was verified after reversed-phase HPLC and provided as a freeze-dried powder (Peptide Synthesis Service, National Institute for Medical Research, London, U.K.), which was resuspended in DMSO to a final stock concentration of 10 mM and used subsequently in the NMT assays.
The NMT assay was carried out in a final volume of 100 µl in 30 mM Tris\HCl, pH 7.4, containing 0.5 mM EGTA, 40 nM peptide, 1 % (w\v) Triton X-100 and partially purified P. falciparum NMT (615 ng\assay). The reaction was initiated by the addition of 0.55 µCi of [$H]myristoyl-CoA (Amersham) and incubation at 37 mC. Samples were removed at various time points and spotted on to P81 phosphocellulose paper (Whatman), which was then washed in three changes of 40 mM Tris\HCl at pH 7. NMT enzyme assays were also carried out after preincubation of the partially purified enzyme (370 ng\assay) in the presence or absence of two known human-NMT inhibitors, 10 mM iodoacetamide and 10 mM diethylpyrocarbonate (DEPC), at room temperature for 15 min. The reaction was then initiated by addition of the peptide substrate and [$H]myristoyl-CoA and transferred to 37 mC for a further 4 h in a reaction volume of 50 µl. The assays were carried out in parallel with human NMT (100 ng\assay) as a positive control at 37 mC for 30 min, unless otherwise stated.
RESULTS AND DISCUSSION
Isolation and sequencing of the full-length P. falciparum NMT gene
The full NMT gene sequence was amplified from both genomic and cDNA. Initially, degenerate oligonucleotide primers based on conserved sequences in NMTs of six other organisms were used to amplify a genomic DNA fragment. This fragment was used to clone a BglII fragment extending beyond the 3h end of the ORF, and sequences extending in the 5h direction were obtained largely from overlapping Vectorette clones. Finally the full genomic and RT-PCR gene sequences were amplified and analysed. Southern-blotting experiments suggested that NMT is a single-copy gene in P. falciparum (results not shown). The amplification of P. falciparum NMT as an RT-PCR product indicates that the mRNA for this protein is expressed in the asexual blood stages of the malarial parasite's life cycle.
The full-length NMT cDNA ORF contains 1230 bp, with the potential to encode a 48 kDa protein. The corresponding genomic DNA contains 1617 bp consisting of four exons ; the first exon codes for the first five amino acids in the ORF. The three introns (all of which have the GT\AG boundary consensus) are located towards the 5h end of the coding region and span 117, 126 and 144 bp, respectively. It has been shown that human NMT exists in two forms as a result of differential mRNA splicing, the longer form containing a lysine-rich N-terminal extension [14] . Comparison of both genomic and cDNA sequences upstream of the proposed ATG initiation codon, based on the size of amplified products and sequence analysis, provided no evidence for a similar extended form of the protein in P. falciparum.
An alignment of orthologous NMT sequences showed that the P. falciparum protein conforms to the pattern of extensive sequence conservation in the central and C-terminal regions of the protein (an alignment with three other sequences is shown in Figure 1 ), with most diversity at the N-terminus. The deduced P. falciparum NMT amino acid sequence is approx. 50 % identical to human NMT and approx. 40 % identical to the two fungal enzymes. The N-terminal sequence divergence is most evident in both the Histoplasma capsulatum NMT [2] and the human NMT [13, 14] . H. capsulatum contains an apparent N-terminal extension of 71 residues and human NMT can also contain an N-terminal extension resulting from differential mRNA splicing. This Nterminal extension is postulated to direct the normally soluble enzyme to the ribosomal fraction [16] . Previous studies using S. cere isiae NMT have suggested that the first 59 amino acids are not required for catalytic activity [7] . The data presented here indicate that there is no alternative start site for P. falciparum NMT and that the protein does not contain an N-terminal extension.
All the residues known to participate directly in the enzymic mechanism or play critical regulatory roles in yeast NMT are conserved in the P. falciparum enzyme with the exception of Ile")!, which is replaced by Val, and His%', which is Tyr as in other non-yeast enzymes. A conserved cysteine residue (Cys##* in Figure 1 ) is replaced by Ala in P. falciparum NMT. The two PROCITE signature sequences that uniquely identify NMT proteins, (KFGXGDG) and [(E\D)(I\V)NFLC(V\I)HK], are present.
Expression of active P. falciparum NMT in E. coli
To determine whether or not the protein could be expressed in an enzymically active form, the 1230 bp NMT cDNA obtained by RT-PCR was cloned into the plasmid pTrcHis-C and used to transform E. coli TOP10 cells. E. coli has no endogenous NMT activity [21] . The recombinant protein was expressed as a Nterminal hexa-histidine and Xpress4 epitope-tagged fusion protein and partially purified by affinity chromatography using a nickel-chelate (Ni-NTA) column. After induction of protein expression the NMT fusion protein was detectable by Western blotting using monoclonal antibodies anti-pentaHis (results not shown) and anti-Xpress4 directed at the N-terminal tag coded by the expression vector (Figure 2 ). The fusion protein was purified partially by binding to a Ni-NTA column and eluted with 1.0 M imidazole. The antibodies recognized a 47 kDa protein, in good agreement with the predicted size, in the crude lysate of bacteria expressing P. falciparum NMT (Figure 2 , lane 1) and material eluted from the nickel column (Figure 2, lane 3) , but did not recognize proteins in the lysate of bacteria containing the expression vector alone (Figure 2, lanes 4-6) .
The assay for NMT activity is based on the transfer of the [$H]myristoyl group from myristoyl-CoA to a synthetic peptide and the binding of the [$H]myristoylated peptide to phosphocellulose paper [19] . In the complete reaction mixture containing P. falciparum NMT and a peptide substrate based on the Nterminal amino acid sequence of the P. falciparum ARF1 protein Figure 1 The deduced amino acid sequence of P. falciparum NMT aligned with that of two fungal and a corresponding human sequence
The P. falciparum NMT (Pf) sequence is aligned with those of S. cerevisiae (Sc ; accession no. M23726) and C. albicans (Ca ; accession no. M80544), two fungal enzymes that have been used for X-ray crystallographic studies, and with the short form of human NMT1 (Hs ; accession no. M86707). Residues identical in the P. falciparum sequence to one or more of the other three sequences are shaded ; gaps inserted to improve the alignment are shown (.). Residues discussed in the text are indicated (*), together with the two PROCITE NMT signature sequences (underlined). The alignment was made using the program PileUp (Genetics Computer Group4).
Figure 2 Expression of P. falciparum NMT in E. coli and a partial purification
A lysate was prepared from bacterial cells and the soluble fraction applied to a Ni-NTA column. After washing the column, bound material was eluted with 1.0 M imidazole. Samples of each fraction were resolved by SDS/PAGE analysis on a 12.5 % gel and the proteins analysed by Western blotting using the Anti-Xpress4 monoclonal antibody. In lane 1, the total lysate from bacteria containing the P. falciparum NMT plasmid construct ; lane 2, the proteins not bound to the column ; lane 3, proteins bound to the column and eluted with imidazole ; lane 4, the total lysate from control bacteria containing the plasmid without the NMT sequence ; lane 5, proteins in the control lysate not bound to the column ; lane 6, proteins in the control lysate bound to the column and eluted with imidazole. The mobilities of the molecular-mass markers are shown on the left. In lanes 1 and 3 a 47 kDa band corresponds to the full-length P. falciparum NMT fusion protein.
[17], enzyme activity was detected, whereas in the absence of either peptide or NMT expression only background levels of radiolabel incorporation were observed (Figure 3 ).
Figure 3 Recombinant P. falciparum NMT is enzymically active
The time course for P. falciparum NMT activity of protein purified from E. coli using the Ni-NTA column. Samples were assayed as described in the Materials and methods section. The results of a representative experiment from three performed are shown as the means of duplicate samples (which consistently differed by less than 10 %). , P. falciparum NMT with synthetic peptide substrate ; #, P. falciparum NMT without peptide substrate ; , synthetic peptide substrate without NMT ; >, control eluate with synthetic peptide substrate ; $, control eluate without peptide substrate ; 100 % activity corresponds to an incorporation of 16 297 c.p.m. 3 H.
Although the level of expression in E. coli was not high (12 µg:l of bacterial culture −" ), the protein could be detected by Western blotting and by enzymic activity. In view of the skewed codon usage, typical of P. falciparum genes, it is likely that expression levels would be improved by re-synthesis of the gene using E. coli-preferred codons. Furthermore, additional purification steps will be required to obtain homogeneous enzyme. The sequence of the peptide used is consistent with the consensus The inhibition of human and P. falciparum NMT activities by treatment with 10 mM iodoacetamide or 10 mM DEPC for 20 min at 37 mC was measured. Samples were assayed as described in the Materials and methods section using an incubation period of 4 h to allow maximal incorporation. The results of a representative experiment are shown as the means of duplicate samples (which differed consistently by less than 10 %). In this assay 100 % activity corresponds to incorporations of 8645 and 6950 c.p.m. 3 
Inhibition of P. falciparum NMT activity by chemical modification
The sensitivity of both human and P. falciparum NMT to inhibition by iodoacetamide and DEPC was investigated. Using these inhibitors, the recombinant P. falciparum NMT could be distinguished from the human enzyme. Human NMT is partially inhibited by 5 mM iodoacetamide and completely inhibited by 10 mM DEPC [20] . P. falciparum NMT expressed in E. coli was not inhibited by 10 mM iodoacetamide or 10 mM DEPC (Table  1) , conditions under which human NMT activity was inhibited by 50 % and 75 %, respectively. Although it had been suggested previously that one or more of the conserved cysteine and histidine residues are involved directly in the catalytic transfer mechanism [22] , this is now considered unlikely based on the structural studies [12] . Whether or not the replacement of the conserved cysteine residue (residue 229 in Figure 1 ) by Ala in P. falciparum NMT results in insensitivity to iodoacetamide inhibition remains to be determined. Further studies are required of the effects of other NMT inhibitors on the purified enzyme and on parasite cultures to determine whether or not anti-N-myristoyltransferase drugs are anti-parasitic.
